The CA125 regression rate to predict overall survival differ between paclitaxel-containing regimen and nonpaclitaxel regimen in patients with advanced ovarian cancer-Reference-Cited by-同舟云学术

The CA125 regression rate to predict overall survival differ between paclitaxel-containing regimen and nonpaclitaxel regimen in patients with advanced ovarian cancer

Published:2002-09 Issue:5 Volume:12 Page:435-437
ISSN:1048-891X
Container-title:International Journal of Gynecological Cancer
language:en
Short-container-title:Int J Gynecol Cancer

Author:

Tsuda H.,Hashiguchi Y.,Nakata S.,Deguchi M.,Negoro S.,Ishiko O.,Yamamoto K.

Publisher

BMJ

Subject

Obstetrics and Gynaecology,Oncology

Reference9 articles.

1. CA 125 half-life in ovarian cancer: a multivariate survival analysis

2. A risk model for ovarian carcinoma patients using CA 125: Time to normalization renders second-look laparotomy redundant

3. CA 125 regression after two completed cycles of chemotherapy: lack of prediction for long-term survival in patients with advanced ovarian cancer

4. Cyclophosphamide and Cisplatin Compared with Paclitaxel and Cisplatin in Patients with Stage III and Stage IV Ovarian Cancer

5. Modulation of tumour marker CA-125 expression in cultured ovarian carcinoma cells

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. CA125-related tumor cell kinetics variables after chemotherapy in advanced ovarian cancer: a systematic review;Clinical and Translational Oncology;2015-11-06

2. A critical review of the analytical approaches for circulating tumor biomarker kinetics during treatment;Annals of Oncology;2014-01

4. Clinical significance of CA125 regression in chemotherapy of advanced ovarian cancer;The Chinese-German Journal of Clinical Oncology;2012-03

5. Serum and tissue biomarkers as predictive and prognostic variables in epithelial ovarian cancer;Critical Reviews in Oncology/Hematology;2009-01